Chemoprevention of Oral Premalignant Lesions

Pfizer

Status and phase: Completed; Phase 2

Conditions: Precancerous Conditions

Treatments: Drug: Celecoxib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00036283

NQ4-00-02-011

Details and patient eligibility

About

Reduction in size and number of oral premalignant lesions

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 8mm oral premalignant lesion that has not been biopsied in the past 6 months

Exclusion criteria

• Taking >100mg daily dose of NSAIDS (Non-steroidal anti-inflammatory drugs)

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind